Gritstone bio, Inc. is a biotechnology company that is presently engaged in the development of innovative vaccine-based immunotherapy candidates for the treatment of cancer and infectious diseases in the clinical-stage. Its flagship product candidate is GRANITE, a neoantigen-based immunotherapy that is currently undergoing Phase 2/3 clinical trials targeting microsatellite stable colorectal cancers and other solid tumors. The company is also developing SLATE, which is an off-the-shelf immunotherapy candidate being studied in Phase 2 clinical trials for the treatment of metastatic solid tumors. Gritstone bio's portfolio also includes CORAL, which is a SARS-CoV-2 vaccine platform designed for broader immunity and protection against SARS-CoV-2 variants along with a therapeutic vaccine candidate intended to treat and cure HIV infection. Gritstone bio, Inc.'s strategic collaborations include agreements with bluebird bio, Inc., Gilead Sciences, Inc., and license agreement with Genevant Sciences GmbH. The company, formerly known as Gritstone Oncology, Inc., changed its name to Gritstone bio, Inc. in May 2021. Headquartered in Emeryville, California, Gritstone bio, Inc. was founded in 2015 with an ultimate goal to address unmet medical needs through developing new and innovative immunotherapies.
Gritstone bio's ticker is GRTS
The company's shares trade on the NASDAQ stock exchange
They are based in Emeryville, California
There are 51-200 employees working at Gritstone bio
It is gritstonebio.com
Gritstone bio is in the Healthcare sector
Gritstone bio is in the Biotechnology industry
The following five companies are Gritstone bio's industry peers: